低密度脂蛋白降胆固醇药物:一个叙事评论
Nicola Ferri1,2, Massimiliano Ruscica3,4, Sergio Fazio5
1Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy.
降胆固醇药物已经显著发展,从早期的生物合成抑制剂到针对PCSK9和肠道吸收的现代疗法. 这些进展为高胆固醇血症和动脉样硬化心血管疾病提供了量身定制的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 生物化学 生物化学
背景情况:
- 1972年发现紧素标志着降胆固醇药物开发的开始.
- 1987年推出的他类药物成为治疗动脉样硬化心血管疾病的基石.
- 不断发展的疗法通过除了他类药物之外的多种机制来解决高胆固醇血症.
研究的目的:
- 审查关键胆固醇降低剂的药理特性.
- 总结这些药物的临床疗效在管理高胆固醇血症.
- 突出针对动脉样硬化心血管疾病患者的量身定制的治疗策略.
主要方法:
- 科学文献的叙述性审查.
- 对药物作用机制的分析.
- 对临床试验数据的有效性和安全性的评估.
主要成果:
- 鉴定了compactin作为一种早期胆固醇生物合成抑制剂.
- 开发了他类药物,埃泽蒂米布,PCSK9抑制剂 (单克隆抗体和siRNA),以及bempedoic酸.
- 这些药物在降低LDL-C和减少心血管事件方面已证明有效.
结论:
- 现在可以使用各种各样的降脂疗法.
- 这些药物使得高胆固醇血症的个性化治疗方法成为可能.
- 高胆固醇血症的有效管理对于预防动脉样硬化心血管疾病至关重要.
更多相关视频
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antihypertensive Drugs: Direct Renin Inhibitors
